Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations
Notice Number:

Key Dates

Release Date:

March 15, 2021

First Available Due Date:
May 05, 2021
Expiration Date:
May 06, 2021

Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)


NINDS is interested in applications for supplements to human subjects awards administered by the NINDS to conduct research on the effects of COVID-19 on the development of, or disease progression in, Alzheimer's Disease-Related Dementias (ADRDs). ADRDs include Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Mixed Etiology Dementias (MED). Older adults are known to be especially vulnerable to COVID-19 infection, and COVID-19 infection commonly presents with neurological signs and symptoms. The effect of COVID-19 exposure on subjects who have, or are at risk for developing ADRDs is unclear. Investigators who are currently researching ADRD or at-risk for ADRD populations are encouraged to apply for additional support to examine the impact of COVID-19 in these subjects. Research topics of interest may include (but are not limited to):

  • The effect of symptomatic or asymptomatic COVID-19 infection on progression to cognitive impairment or dementia in populations that are at risk for ADRDs.
  • The effect of symptomatic or asymptomatic COVID-19 infection on progression of dementia in patients with existing ADRDs.
  • COVID-19 induced hyposmia/dysgeusia as a risk factor(s) for progression to dementia in at-risk for ADRD populations, or progression of dementia in people with ADRD diagnoses..
  • Evidence of new or worsening ADRD-related neurophysiology (e.g., small vessel disease, ischemia, or atrophy on MRI, alterations in blood or CSF proteins, etc.) that occur after symptomatic or asymptomatic COVID-19 infection.

Studies proposed in the supplement application must be within scope of the original parent application’s research. Applicants may request funds to cover the costs of additional subject enrollment, personnel, or assessments (e.g., COVID-19 testing, cognitive assessments, smell testing, neuroimaging).

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

  • Application Due Date(s) – May 5, 2021, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include “NOT-NS-21-037” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one or two year(s) of support only, as long as the request does not exceed the duration of the parent application.
  • The Research Strategy section of the application is limited to 6 pages.
  • Application budgets must reflect the actual needs of the proposed project. Supplement budget requests may not exceed $666,000 per year in direct costs or 100% of the direct costs of the current year of the parent award (exclusive of Facilities and Administrative costs on sub-contracts), whichever amount is lower.. Applications that want to propose higher budgets must receive permission from the project officer and IC Contact prior to submission.
  • The application Abstract section should describe the proposed supplement, and the Research Strategy section should include a summary or abstract of the funded parent award or project. The Research Strategy should state the relevance to the parent award and AD/ADRD, and articulate the component(s) and any IC-specific priorities that the supplement is addressing.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.
  • The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.


Please direct all inquiries to:

Dr. Debra Babcock
National Institute of Neurological Disorders and Stroke
Telephone: 31-496-9964

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices